Advertisement
Canada markets close in 6 hours 20 minutes

  • S&P/TSX

    21,787.59
    +79.15 (+0.36%)
     

  • S&P 500

    5,007.15
    -3.97 (-0.08%)
     

  • DOW

    37,905.28
    +129.90 (+0.34%)
     

  • CAD/USD

    0.7275
    +0.0011 (+0.15%)
     

  • CRUDE OIL

    82.72
    -0.01 (-0.01%)
     

  • Bitcoin CAD

    88,904.10
    +3,377.84 (+3.95%)
     

  • CMC Crypto 200

    1,332.42
    +19.80 (+1.51%)
     

  • GOLD FUTURES

    2,397.00
    -1.00 (-0.04%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6080
    -0.0390 (-0.84%)
     

  • NASDAQ

    15,519.31
    -82.19 (-0.53%)
     

  • VOLATILITY

    18.65
    +0.65 (+3.61%)
     

  • FTSE

    7,831.41
    -45.64 (-0.58%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6815
    -0.0006 (-0.09%)
     
MARKETS LIVE BLOG:

STOCKS OPEN MIXED AFTER ISRAEL STRIKE-FUELLED TUMBLE

Shares of Netflix, the first of the megacap techs to report, slide in early trading

Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference

Bellerophon Therapeutics, Inc.
·1 min read
Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc.

WARREN, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced a poster presentation at the upcoming American Thoracis Society (ATS) 2022 International Conference, being held May 13-18, 2022, in San Francisco, CA.

Presentation Details

  • Session C103: It's not just about IPF

  • Poster Title: A Phase 2 Trial of INOpulse in Patients with Sarcoidosis Associated Pulmonary Hypertension (SAPH) Requiring Supplemental Oxygen

  • Presenter – Robert Baughman, M.D., Professor of Medicine at the University of Cincinnati

  • Date/Time – Tuesday, May 17, 2022, at 2:15 PM Pacific Time

  • Location – Room 9-10 (South Building, Exhibition Level), Moscone Center

ADVERTISEMENT

The ePoster will be released on the day of presentation, will be available in the ePoster Viewing Site and accessible to conference attendees. Additional details can be found at the ATS 2022 website.

About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.

Contacts

LifeSci Advisors:

Brian Ritchie

(212) 915-2578

britchie@lifesciadvisors.com